We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+15.53%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$254M
AUM Growth
-$32.6M
Cap. Flow
-$20.3M
Cap. Flow %
-8%
Top 10 Hldgs %
68.51%
Holding
44
New
8
Increased
7
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$9.69M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$8.8M
3
NTLA icon
Intellia Therapeutics
NTLA
+$8.27M
4
DERM
Dermira, Inc.
DERM
+$7.51M
5
AKAO
Achaogen Inc
AKAO
+$5.47M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$20.3M
2
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$10.5M
3
EPZM
Epizyme, Inc
EPZM
+$9.41M
4
AIMT
Aimmune Therapeutics
AIMT
+$7.07M
5
KITE
Kite Pharma, Inc.
KITE
+$6.89M

Sector Composition

Rank Sector Weight
1 Healthcare 86.15%
2 Miscellaneous 13.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FWP
26
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.53M 0.6%
12,047
-1,814
-13% -$245K
IMGN
27
CALL
DELISTED
Immunogen Inc
IMGN
$922K 0.36%
299,500
– –
AKTX
28
Akari Therapeutics
AKTX
$20.8M
$856K 0.34%
79
-36
-31% -$464K
TSRO
29
DELISTED
TESARO, Inc.
TSRO
$773K 0.3%
+9,200
New +$410K
ADXS
30
DELISTED
Advaxis Inc
ADXS
$751K 0.3%
+6,187
New +$793K
EIGR
31
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$281K 0.11%
473
-5,845
-93% -$3.55M
CYTK icon
32
CALL
Cytokinetics
CYTK
$10B
– –
-250,000
Closed -$1.76M
LRMR icon
33
CALL
Larimar Therapeutics
LRMR
$417M
– –
-833
Closed -$67K
DCOY
34
Decoy Therapeutics
DCOY
$1.9M
– –
-1
Closed -$6.32M
XNTK icon
35
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
– –
-297,200
Closed -$15.4M
ATYR
36
aTyr Pharma
ATYR
$53M
– –
-5,354
Closed -$295K
GBT
37
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-28,032
Closed -$445K
FPRX
38
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-500,757
Closed -$20.3M
AIMT
39
DELISTED
Aimmune Therapeutics
AIMT
– –
-521,366
Closed -$7.07M
ONCE
40
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-8,700
Closed -$257K
LOXO
41
DELISTED
Loxo Oncology, Inc
LOXO
– –
-150,308
Closed -$4.11M
KITE
42
DELISTED
Kite Pharma, Inc.
KITE
– –
-150,000
Closed -$6.89M
CPXX
43
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-950,000
Closed -$10.5M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2016 Portfolio in Review

As of Q2 2016, EcoR1 Capital held 44 positions worth $254M, down 11% from $286M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

EcoR1 Capital withdrew a net $20.3M in Q2 2016, closing 12 positions and reducing 10 holdings. Its most notable exit was Five Prime Therapeutics, Inc., an estimated $20.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Intra-Cellular Therapies Inc. worth $9.51M.

  • EcoR1 Capital's largest Q2 2016 buy was Intra-Cellular Therapies Inc.: 244,950 shares worth $9.51M.
  • EcoR1 Capital added most to Lakefront Biotherapeutics American Depositary Shares in Q2 2016, an estimated $9.69M increase.
  • EcoR1 Capital's biggest Q2 2016 reduction was Epizyme, Inc, cutting an estimated $9.41M.
  • EcoR1 Capital fully exited Five Prime Therapeutics, Inc. in Q2 2016, selling an estimated $20.3M.
  • EcoR1 Capital's ten largest holdings make up 69% of its $254M portfolio in Q2 2016.
  • EcoR1 Capital opened 8 new positions and closed 12 in Q2 2016.
  • EcoR1 Capital's portfolio value fell 11% quarter-over-quarter to $254M.

Based on EcoR1 Capital's 13F filing for Q2 2016, filed 15 Aug 2016.